Overview

A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to demonstrate maintenance of treatment efficacy when transferring adult outpatients with opioid dependence, who are clinically stabilized on 8 mg or less of sublingual (SL) buprenorphine (BPN), to 4 Probuphine implants compared to SL BPN. The secondary objective of the study is to confirm safety of 4 Probuphine implants in adult outpatients with opioid dependence who are clinically stabilized on 8 mg or less of SL BPN.

Phase:

Phase 3

Details

Lead Sponsor:

Braeburn Pharmaceuticals
Titan Pharmaceuticals

Treatments:

Buprenorphine